Lyon

• A Phase 1 Study of PRT3789 in Participants with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation Ended
  2022-502850-14-00 1 2023-09-25 gastroesophageal junction
• Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended
  2022-502196-31-00 10 2023-08-21 Advanced or Recurrent Endometrial Cancer
• A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with i … Ended
  2023-508267-69-00 3 2023-08-11 Subjects with Aadvanced solid tumors for whom life-prolonging therapie
• A Study of TAK-676 as Single Agent and TAK-676 in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Ended
  2023-505627-30-00 7 2023-07-26 Solid Neoplasm
• Pharmacokinetics of anti-lymphocyte serum in the prevention of GvHD in children and adults receiving allogeneic hematopoietic stem cell tran … Ended
  2022-501594-39-00 6 2023-07-17 pediatric and adult patients undergoing HSC allograft procedures with
• A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects Wi … Ended
  2022-501618-70-00 7 2023-06-27 BRAF-V600 Mutant Solid Tumors including Melanoma, Non-small cell lung
• A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus … Ended
  2022-500177-13-00 4 2023-06-02 Metastatic Colorectal Cancer (mCRC)
• Evaluation of Amivantamab Infusion Related Reaction Mitigation Ended
  2023-506578-11-00 4 2023-04-25 EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer
• A Phase I Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTA0-Tyr3-Octreotate in Children … Ended
  2024-515552-21-00 3 2023-04-17 Recurrent or refractory neuroblastoma.
• INCA 32459-101: A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies Ended
  2022-501505-13-00 1 2023-03-31 Metastatic melanoma
• Phase 1b study investigating the association of NP137 with mFOLFIRINOX in locally advanced pancreatic ductal adenocarcinoma LAP NET 1 Ended
  2022-500905-42-00 3 2023-03-24 pancreatic ductal adenocarcinoma
• OMX-0407 Phase I Study Ended
  2024-514554-75-00 1 2023-03-16 Previously treated unresectable solid tumours
• A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects with Metastatic Solid Tumors Ended
  2023-508529-29-00 9 2023-03-08 Metastatic Solid Malignant tumors
• A proof-of-concept study to examine QUC398 in participants with knee osteoarthritis Ended
  2023-509274-28-00 4 2023-02-03 Knee osteoarthritis
• A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activ … Ended
  2022-500116-18-00 3 2023-01-09 Advanced Solid Tumors
• Relatlimab + Nivolumab in Pediatric and Young Adult Lymphomas (RELATIVITY-069) Ended
  2023-503715-14-00 9 2022-12-29 Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lym
• Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 year … Ended
  2024-512095-35-00 9 2022-12-27 Relapsed or refractory neuroblastoma and other solid tumors (including
• An Open-Label Extension Study for Patients who Previously Completed Study ISEE2008 (GATHER2) Ended
  2024-515185-13-00 5 2022-12-21 geographic atrophy
• Ezurpimtrostat autophagy inhibitor in association with Atezolizumab-Bevacizumab in first line treatment of unresectable hepatocellular carci … Ended
  2022-502078-17-00 4 2022-12-15 unresectable hepatocellular carcinoma
• Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients with Platinum-Resistant Ep … Ended
  2024-513230-38-00 5 2022-12-15 Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peri
• Clinical study to investigate the efficacy of botensilimab (AGEN1181) in patients with advanced melanoma refractory to prior checkpoint inhi … Ended
  2022-500652-37-00 4 2022-12-01 Advanced melanoma refractory to prior checkpoint inhibitor therapy
• A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRα) Antibody Dru … Ended
  2024-513708-33-00 1 2022-11-23 Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primar
• VItamin C in Thermal injuRY: The VICToRY Trial A phase III multi-center randomized trial Ended
  2023-504772-21-00 4 2022-11-22 Severely burned patients
• Study to see how safe is TNG908 at different doses in patients with solid tumors that have a gene called MTAP missing Ended
  2024-511976-34-00 7 2022-10-31 "Ph1: •Locally advanced (LA) or metastatic MTAP-deleted (met.MTAP-del.

Showing 769–792 of 875 trials